Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,289 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05849467RecruitingPhase 1
Testing how the brain absorbs anti–CD8 therapy in nervous system disease
This Phase 1 study tests a small drug (called an anti–CD8+ T cell minibody) to see how much reaches the brain. It may help researchers understand how to deliver similar treatments for multiple sclerosis, progressive multifocal leukoencephalopathy (PML), or other brain inflammation when the brain’s protective barrier is “open.”
Bethesda, MarylandAges 18–120 - NCT05865002RecruitingPhase 1
Safety and drug test for AUR107 in advanced cancers
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05870995RecruitingPhase 2
Chemo plus targeted conditioning for hard-to-treat AML
This trial studies a specific chemotherapy plan (called sequential CLAG-Ven) with a gentler “conditioning” treatment before a transplant or donor-based therapy. It may help people with refractory or quickly relapsing acute myeloid leukemia (AML) who have a suitable family or matched donor and can meet certain organ function and infection rules.
Shanghai, Shanghai MunicipalityAges 16–65 - NCT05983809Recruiting
Balance and walking rehab using technology for MS
This trial tests a new type of balance and walking training for people with multiple sclerosis. It uses technology to help improve your stability and gait, which may help you move more safely and confidently.
Roma, RMAges 18–65 - NCT05984147RecruitingPhase 1
Study of oral drug AUR108 for advanced lymphoma
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
Visakhapatnam, Andhra PradeshAges 18–99 - NCT06068582Recruiting
Keep your memory sharp and stay at work with MS
This study tests a program of physical and mental exercises designed to slow down memory and thinking problems in people with multiple sclerosis, and help them stay employed longer.
AmsterdamAges 18–67 - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+ - NCT06221631Recruiting
Brain aging in MS and healthy people
This study compares how the brain ages in people with multiple sclerosis (MS) and healthy volunteers. It uses MRI scans and other tests to understand brain aging better.
Bern, Canton of BernAges 18–65 - NCT06270641Recruiting
Increasing physical activity for adults with MS
This study tests whether using a phone app (ExerciseRx) can help people with multiple sclerosis become more active. You may be able to join if you are not currently very active and can walk without needing a cane or walker.
Seattle, WashingtonAges 18 years+ - NCT06280742Recruiting
Brain inflammation in multiple sclerosis: a PET-MRI imaging study
This study uses a special PET-MRI scan to look at brain inflammation in people with relapsing-remitting multiple sclerosis (RRMS). It may help researchers understand how inflammation changes when starting a stronger MS treatment.
LyonAges 18 years+ - NCT06287398RecruitingPhase 2
Epcoritamab and chemo before stem cell transplant for relapsed large B-cell lymphoma
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
Melbourne, VictoriaAges 18 years+ - NCT06312046Recruiting
Thinking and Movement in MS: A Balance Study
This study tests how thinking and movement interact in people with MS who have some balance problems. It aims to find ways to improve daily function.
Stockholm, Stockholm CountyAges 18–65 - NCT06374108Recruiting
Resistance training and walking in multiple sclerosis
This study tests whether resistance training (like lifting weights) can improve how your brain and muscles communicate, and whether that helps your walking. It's designed for people with MS who have some walking difficulties.
Aarhus, Central JutlandAges 18 years+ - NCT06424301RecruitingEarly Phase 1
Targeted gene therapy for hard-to-treat retinoblastoma
This trial tests an experimental drug that targets a specific gene (NUDT21) to treat retinoblastoma that has not responded to standard treatments. It is for children who have active tumor in only one eye and whose only other option is to remove the eye, but who want to try to save the eye instead.
ShanghaiAges 6 months+ - NCT06428006RecruitingPhase 2
Sleep therapy for insomnia in multiple sclerosis
This study tests whether a talking therapy (cognitive behavioral therapy for insomnia) can help people with multiple sclerosis who have trouble sleeping. It is done online, so you can join from home.
Kansas City, KansasAges 18–65 - NCT06461481Recruiting
Follow-up strategies for de-escalating multiple sclerosis treatment
This study tests different ways of monitoring people with relapsing-remitting MS who are reducing or stopping their medication. It aims to find the safest follow-up approach and may help guide future treatment decisions for those with stable disease.
DüsseldorfAges 18 years+ - NCT06461741Recruiting
EMG biofeedback training for balance in MS
This study tests whether a special training method that uses muscle signals (called EMG biofeedback) can help people with MS improve their walking and balance. If you have problems with walking or balance and your MS is stable, you may be able to join.
Hamilton, OntarioAges 18–80 - NCT06463743RecruitingPhase 2
Metformin for aging people with MS
This study tests whether metformin, a common diabetes drug, can help people with multiple sclerosis (MS) as they age. It may be used alone or added to your current MS treatment, and the goal is to see if it slows down aging-related changes in MS.
Buffalo, New YorkAges 55–75 - NCT06495138Recruiting
Eye exercises for dizziness in multiple sclerosis
This study tests a new type of eye exercise to help with dizziness and balance problems in people with multiple sclerosis (MS). The exercise involves moving your head and eyes in a specific way to retrain your balance system.
Atlanta, GeorgiaAges 18–89 - NCT06496048RecruitingPhase 3
Testing lurbinectedin for small cell lung cancer that has returned
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Jilin CityAges 18 years+ - NCT06501950Recruiting
Measuring silent MS progression with advanced tests
This study is looking for people with MS who are already on a monoclonal antibody therapy. It aims to measure subtle signs of disease progression using advanced tests, even if you feel stable.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT06513429Recruiting
IM19 CAR-T cell therapy for tough lupus cases
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06552416RecruitingPhase 1
Safety study of MT-401-OTS for relapsed AML or MDS
This trial tests a new cell therapy called MT-401-OTS for people aged 65 or older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The goal is to see if this treatment is safe and to find the right dose.
Duarte, CaliforniaAges 65 years+ - NCT06552611RecruitingPhase 1
Spinal cord stimulation for hand function in MS
This study tests whether a gentle electrical stimulation applied to the skin over the spinal cord can help improve hand and arm function in people with MS. If you have MS and difficulty using your hands, you may be able to join.
Seattle, WashingtonAges 21–70
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,289 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.